Global T cell therapy Market

Global T-cell Therapy Market Size, Share, Growth Analysis, By Modality(Research, Commercialized), By Type(CAR T-cell Therapy, T Cell Receptor (TCR)-based), By Indication(Hematologic Malignancies, Solid Tumors), By End User(Hospitals, Specialty Clinics) - Industry Forecast 2024-2031


Report ID: SQMIG35H2210 | Region: Global | Published Date: February, 2024
Pages: 285 | Tables: 117 | Figures: 78

Global T-cell Therapy Market Insights

Global T-cell Therapy Market size was valued at USD 7095.83 million in 2019 and is poised to grow from USD 8344.7 million in 2023 to USD 35898.15 million by 2031, growing at a CAGR of 17.6% in the forecast period (2024-2031).

One of the main causes of mortality across the globe is cancer. It is predicted that by the end of 2040, there will be an additional 27.5 million cancer cases worldwide, placing a significant financial, emotional, and physical burden on those who are affected, their families, communities, and national health systems. Although there are several treatments available to slow the disease's growth and prevent cancer cells from spreading throughout the body, achieving a long-lasting remission is challenging.

In this regard, immunotherapies, a more recent addition to the spectrum of anticancer treatments, have shown a lot of promise. T-cell therapies (more specifically, CAR-T therapies, TCR therapies, and TIL therapies) have emerged as a promising option among the current efforts made to develop more targeted anti-cancer therapies. This is due to their capacity to eradicate tumor cells from the body with a minimum of treatment-related side effects. Globally, cancer treatment has been transformed by this very effective and promising type of T-cell therapy, which uses the adaptable effector apparatus of the human immune system. This emerging therapeutic area is on its way to become one of the highest valuable markets within the biopharmaceutical sector, given the steadily rising number of cell treatments being developed and introduced.

US T-cell Therapy Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global T-cell Therapy Market size was valued at USD 7095.83 million in 2019 and is poised to grow from USD 8344.7 million in 2023 to USD 35898.15 million by 2031, growing at a CAGR of 17.6% in the forecast period (2024-2031).

Global T cell therapy Market is fragmented and competitive due to the presence of major players. Companies are clamouring to invest in the creation of innovative CAR T-cell treatment due to the exponential increase in the use of precision medicine on a worldwide scale. To maintain a competitive edge and increase their market position in the worldwide Tcell therapy market, leading companies are increasingly focusing on implementing tactics such as adopting new technology, product developments, mergers and acquisitions, joint venture, alliances, and partnerships. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Novartis AG', 'Merck KGaA', 'Gilead Sciences Inc.', 'Kite Pharma, Inc.', 'Juno Therapeutics Inc.', 'Pfizer Inc.', 'Celgene Corporation', 'bluebird bio, Inc.', 'Adaptimmune Therapeutics plc', 'Atara Biotherapeutics, Inc.', 'Mustang Bio, Inc.', 'TCR² Therapeutics Inc.', 'Autolus Therapeutics plc', 'Immunocore Limited', 'Eureka Therapeutics, Inc.', 'Ziopharm Oncology, Inc.', 'Precision Biosciences Inc.', 'Sorrento Therapeutics, Inc.', 'Fate Therapeutics, Inc.', 'Celyad Oncology SA', 'Caribou Biosciences, Inc.'

Following the FDA's approval of Yescarta, Kymriah, and Tecartus, a number of businesses have switched from developing protein- and small-molecule-based therapeutics to adoptive therapies as their primary business model. The market for T-cell treatment has grown as a result of strategic expenditures made in this area by both public and commercial organisations.

CAR T-cell therapies are being used in treatment of solid tumors. CAR T-cell treatment has demonstrated a considerable potential benefit in diffusing midline glioma, a deadly paediatric tumour that affects school-age children and young adults. A study using CAR T cells in animal models to promote prolonged eradication of diffuse midline glioma tumours produced encouraging findings, although some of the animals perished due to toxicity-related problems. For the therapy of brain tumours, intracerebroventricular (ICV) distribution of CAR T was much more effective and less toxic than systemic delivery was found later.

North America held the largest market share of Global T cell therapy Market in 2021 and accounted for the largest revenue share of around 41% in 2021. Strong research, a thriving industry, and a significant number of clinical trials for T-cell treatments being carried out in the U.S. have all significantly aided in the region's market supremacy. Additionally, the market has grown significantly as a result of the rising number of regulatory approvals in the U.S. and Canada as well as the region's shifting reimbursement environment. Additionally, the expansion of the regional market is aided by the large number of medical facilities that provide CAR-T cell therapy.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global T cell therapy Market

Product ID: SQMIG35H2210

$5,300
BUY NOW GET FREE SAMPLE